Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Amberg

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Regulatory Toxicology and Pharmacology : RTP|January 20, 2016
It's difficult, but important, to make negative predictionsRichard V Williams, Alexander Amberg, Alessandro Brigo, et al.
Frontiers in Toxicology|November 29, 2023
<i>In silico</i> approaches in carcinogenicity hazard assessment: case study of pregabalin, a nongenotoxic mouse carcinogenDouglas A Keller, Arianna Bassan, Alexander Amberg, et al.
Regulatory Toxicology and Pharmacology : RTP|August 7, 2015
Establishing best practise in the application of expert review of mutagenicity under ICH M7Chris Barber, Alexander Amberg, Laura Custer, et al.
Toxicology and Applied Pharmacology|November 18, 2010
Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkersKatja A Matheis, Emmanuelle Com, Jean-Charles Gautier, et al.
Regulatory Toxicology and Pharmacology : RTP|December 29, 2015
Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtainedChris Barber, Alex Cayley, Thierry Hanser, et al.
Journal of Biochemical and Molecular Toxicology|May 9, 2019
Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolitesTimothy Ackerson, Alexander Amberg, Jens Atzrodt, et al.
ALTEX|December 3, 2023
Toward implementing virtual control groups in nonclinical safety studiesEmily Golden, David Allen, Alexander Amberg, et al.
Regulatory Toxicology and Pharmacology : RTP|May 15, 2013
Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impuritiesAndreas Sutter, Alexander Amberg, Scott Boyer, et al.
Toxicology and Applied Pharmacology|October 5, 2010
The enhanced value of combining conventional and "omics" analyses in early assessment of drug-induced hepatobiliary injuryHeidrun Ellinger-Ziegelbauer, Melanie Adler, Alexander Amberg, et al.
Mutagenesis|September 7, 2018
Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?Alexander Amberg, Lennart T Anger, Joel Bercu, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Regulatory Toxicology and Pharmacology : RTP|January 20, 2016
It's difficult, but important, to make negative predictionsRichard V Williams, Alexander Amberg, Alessandro Brigo, et al.
Frontiers in Toxicology|November 29, 2023
<i>In silico</i> approaches in carcinogenicity hazard assessment: case study of pregabalin, a nongenotoxic mouse carcinogenDouglas A Keller, Arianna Bassan, Alexander Amberg, et al.
Regulatory Toxicology and Pharmacology : RTP|August 7, 2015
Establishing best practise in the application of expert review of mutagenicity under ICH M7Chris Barber, Alexander Amberg, Laura Custer, et al.
Toxicology and Applied Pharmacology|November 18, 2010
Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkersKatja A Matheis, Emmanuelle Com, Jean-Charles Gautier, et al.
Regulatory Toxicology and Pharmacology : RTP|December 29, 2015
Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtainedChris Barber, Alex Cayley, Thierry Hanser, et al.
Journal of Biochemical and Molecular Toxicology|May 9, 2019
Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolitesTimothy Ackerson, Alexander Amberg, Jens Atzrodt, et al.
ALTEX|December 3, 2023
Toward implementing virtual control groups in nonclinical safety studiesEmily Golden, David Allen, Alexander Amberg, et al.
Regulatory Toxicology and Pharmacology : RTP|May 15, 2013
Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impuritiesAndreas Sutter, Alexander Amberg, Scott Boyer, et al.
Toxicology and Applied Pharmacology|October 5, 2010
The enhanced value of combining conventional and "omics" analyses in early assessment of drug-induced hepatobiliary injuryHeidrun Ellinger-Ziegelbauer, Melanie Adler, Alexander Amberg, et al.
Mutagenesis|September 7, 2018
Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?Alexander Amberg, Lennart T Anger, Joel Bercu, et al.
Pageof 5